Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
3,650
datasets available to search
ShareScore release 0.9.0
Dataset results
3,650 results for “antibody”
Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment
ClinicalTrials.gov study NCT04558918. IPD Sharing: YES. Countries: 12. Publications: 3.
Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease
ClinicalTrials.gov study NCT04419467. IPD Sharing: YES. Countries: 6. Publications: 1.
Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients
ClinicalTrials.gov study NCT03744910. IPD Sharing: YES. Countries: 15. Publications: 4.
Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT04205812. IPD Sharing: YES. Countries: 17. Publications: 1.
Safety, Tolerability, and Pharmacokinetics of RSV Monoclonal Antibody RSM01 in Healthy Adults
ClinicalTrials.gov study NCT05118386. IPD Sharing: YES. Countries: 1. Publications: 3.
Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART
ClinicalTrials.gov study NCT03787095. IPD Sharing: YES. Countries: 1. Publications: 2.
A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma
ClinicalTrials.gov study NCT02967692. IPD Sharing: YES. Countries: 29. Publications: 3.
Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose
ClinicalTrials.gov study NCT03999996. IPD Sharing: YES. Countries: 2. Publications: 1.
A Multicenter Study to Evaluate the Efficacy and Safety of Cinryze® for the Treatment of Acute Antibody-mediated Rejection in Participants With Kidney Transplant
ClinicalTrials.gov study NCT02547220. IPD Sharing: YES. Countries: 6. Publications: 1.
Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies
ClinicalTrials.gov study NCT01084252. IPD Sharing: YES. Countries: 17. Publications: 2.
Coronavirus Disease 2019 (COVID-19) Antibody Plasma Research Study in Hospitalized Patients
ClinicalTrials.gov study NCT04524507. IPD Sharing: YES. Countries: 1. Publications: 1.
A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)
ClinicalTrials.gov study NCT04776018. IPD Sharing: YES. Countries: 2. Publications: 1.
Longitudinal COVID-19 Antibody Testing in Indiana University Undergraduate Students
ClinicalTrials.gov study NCT04620798. IPD Sharing: YES. Countries: 1. Publications: 2.
Data from: Natural selection on antihelminth antibodies in a wild mammal population
Open the record for dataset details and reuse information.
Data from: Blockade of dengue virus transmission from viremic blood to Aedes aegypti mosquitoes using human monoclonal antibodies
Open the record for dataset details and reuse information.
An imaging flow cytometry dataset for profiling the immunological synapse of therapeutic antibodies
Open the record for dataset details and reuse information.
RosettaAntibody generated models for a dataset of 49 antibody-Fv structures
<p><strong>Structures of antibody-Fv domains computationally generated by RosettaAntibody based on the protocol of </strong><a href="https://www.nature.com/articles/nprot.2016.180?proof=true&draft=marketing">Weitzner, Jeliazkov, Lyskov et al.</a><strong> (Nature Protocols 12, 401–416, 2017). There are 49 antibody targets, with about 2800 decoy structures provided per antibody. A table is also provided with the H3-loop rmsd of each structure from the experimental crystal structure.</strong></p> <p><strong>These structures can be used to evaluate whether a score function can identify the near-native structures from the pool of decoys. These structures can also be used for comparison with other sets of structures generated by other antibody structure prediction programs.</strong></p> <p><strong>The research study on this set is unpublished and a manuscript is under preparation. Please cite Jeliazkov, Frick, Zhou & Gray, “Robustification of RosettaAntibody and Rosetta SnugDock,” in preparation, 2020.</strong></p> <p><strong>The homology modeling stage of RosettaAntibody was run with stringent homolog exclusion settings, excluding CDR templates of over 95% identity and FR templates of over 90% identity. The H3 modeling stage was run as described by <a href="https://www.nature.com/articles/nprot.2016.180">Weitzner, Jeliazkov, Lyskov et al.</a> (Nature Protocols 12, 401–416, 2017). </strong></p> <p><strong>The set of 49 antibody-Fv domains was originally compiled by <a href="https://academic.oup.com/peds/article/29/10/409/2462315">Marze et al. </a>(Protein Eng. Des. Sel. 29(10), 409-418, 2016). The dataset was first used to evaluate CDR-H3 loop rmsds in <a href="https://www.jimmunol.org/content/early/2016/11/18/jimmunol.1601137">Weitzner and Gray </a>(J. Immunology 198(1):505-515, 2017).</strong></p> <p><strong>The dataset can be extracted on a linux interface using: </strong></p> <p><strong> tar -xvzf <a href="https://www.zenodo.org/api/files/c2ba9da2-0d46-4aba-adbf-8ddd39b52b29/decoys_rosettaantibody_20200323.tar.gz?versionId=df264fc5-c79c-47b4-82bf-d1cda1e025e2">decoys_rosettaantibody_20200323.tar.gz</a> </strong></p> <p><strong>When extracted the output comprises RosettaAntibody generated models for 49 antibodies in the format:</strong></p> <p><strong><Antibody pdb id> / model-<id 1>.relaxed_<id 2>.pdb.gz</strong></p> <p><strong>The Rosetta "ref2015" scores (ref2015_score) and rmsd of the H3 loop (h3_rmsd) for every model (model) is provided in model_scores_and_rmsds.txt . RMSDs are calculated with respect to the corresponding crystal structure (pdb id) over all heavy atoms in the h3 loop (93–102 in Chothia numbering) after superposition of the framework residues. ID 1 comes from the homology model source (lower is better). ID 2 indicates the loop model.</strong></p> <p><strong>The decoy PDB files contain additional metrics following the ATOM records such as VH–VL relative orientation metrics (from Marze et al.) and per-residue Rosetta scores. Caveat: the “RMS” values reported within the decoy files were calculated against the input homology model and not the crystal structures (whereas the model_rmsds.txt file contains the H3 rmsds w.r.t. crystal).</strong></p>
Mass spectrometry output SILAC labelled (F/Y) biological replicate 2 - anti-HLA-A29 antibody DK1G8
<p>Mass spectrometry output from SILAC labelled (F/Y) ERAP2 WT versus (CRISPR Cas9-mediated) ERAP2-KO lymphoblastoid cell line from a Birdshot Uveitis patient (ERAP1 hap10/10 ERAP2 hapA/A). Peptides were eluted from immuno-purifications with anti-HLA-A29 antibody DK1G8. The dataset was used for subsequent filtering and differential expression analysis by <em>limma</em>. </p>
Mass spectrometry output SILAC labelled (F/Y) biological replicate 2 - anti-HLA-ABC antibody W6/32
<p>Mass spectrometry output from SILAC labelled (F/Y) ERAP2 WT versus (CRISPR Cas9-mediated) ERAP2-KO lymphoblastoid cell line from a Birdshot Uveitis patient (ERAP1 hap10/10 ERAP2 hapA/A). Peptides were eluted from immuno-purifications from HLA-A29-negative (DK1G8-negatively selected) fractions with anti-HLA-ABC antibody W6/32. The dataset was used for subsequent filtering and differential expression analysis by <em>limma</em>. </p>
Predicting the presence and titer of rabies virus neutralizing antibodies from low-volume serum samples in low-containment facilities
<p>Python Script. Cell count outputs were converted into a standardized spreadsheet using a Python version 3.7.2 script</p> <p>Codes for binomial and lognormal model</p> <p>code to obtain the images from the model results</p> <p>data to run the models, data result from the models</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.